Fabry disease is a genetic disease due to an enzymatic deficit. A screening of this disease allows patients to benefit from an enzyme replacement therapy and prevent the occurrence of life threatening manifestations such as an ischemic stroke. The purpose of the study is to determinate the prevalence of Fabry disease in a population of male patients hospitalized for an ischemic stroke. This study, with a screening of Fabry disease, allows the patients to make a precise diagnosis of their ischemic stroke and to facilitate the screening of the other members at the facility.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
889
Ischemic stroke hospitalized
Hôpital Gabriel Montpied
Clermont-Ferrand, France
Fabry disease's screening (Positive microdosage confirmed by a macrodosage)
Time frame: Positive microdosage confirmed by a macrodosage
Describe and compare the characteristics of patients affected by Fabry disease and patients who are not affected Identify clinical and neuroradiological predictive elements of Fabry disease
Time frame: patients affected by Fabry disease
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.